MREO · Mereo BioPharma Group plc

$0.31 +0.01 (+2.58%)

Market Cap

$241.10M

798.09M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Denise Scots-Knight	CEO	$565,107	$254,298	$285,358	$1,043,403	—	$71,157	$2,219,323
Charles Sermon	General Counsel and Business Development	$415,651	$162,104	$99,540	$362,923	—	$48,031	$1,088,249
Christine Fox	CFO	$378,120	$151,248	$91,043	$340,240	—	$40,400	$1,001,051

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Denise Scots-Knight	CEO	$506,809	$304,085	—	$1,358,134	—	$68,219	$2,237,247
General Counsel	—	$372,772	$186,386	—	$339,533	—	$51,198	$949,889
Christine Fox	CFO	$332,833	$166,416	—	$271,627	—	$40,063	$810,939

Key facts CIK 1719714 CUSIP 589492107 13F (30d) 5 filings 5 filers Visit website Investor relations